about
A novel POLE mutation associated with cancers of colon, pancreas, ovaries and small intestineMR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts.Outcomes and prognostic factors of patients with stage IB and IIA pancreatic cancer according to the 8th edition American Joint Committee on Cancer criteria.Predicting patient survival after pancreaticoduodenectomy for malignancy: histopathological criteria based on perineural infiltration and lymphovascular invasionFabrication of gold nanoparticles for targeted therapy in pancreatic cancer.Resectable carcinoma developing in the remnant pancreas 7 years and 10 months after distal pancreatectomy for invasive ductal carcinoma of the pancreas: report of a case.A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma.High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer.PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.Pancreatic ductal adenocarcinoma: long-term survival does not equal cureIdentification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma.Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma.Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma.Does the mechanism of lymph node invasion affect survival in patients with pancreatic ductal adenocarcinoma?Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancerVery Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing AnalysisPrognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal AdenocarcinomaEffect of thalidomide in combination with gemcitabine on human pancreatic carcinoma SW-1990 cell lines in vitro and in vivo.Local iontophoretic administration of cytotoxic therapies to solid tumorsMulti-institutional analysis of pancreatic adenocarcinoma demonstrating the effect of diabetes status on survival after resectionMultidisciplinary neoadjuvant management for potentially curable pancreatic cancer.Can pancreaticoduodenectomy performed at a comprehensive community cancer center have comparable results as major tertiary center?Histopathological tumour viability after neoadjuvant chemotherapy influences survival in resected pancreatic cancer: analysis of early outcome data.Rare long-term survivors of pancreatic adenocarcinoma without curative resection.A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma.Young patients undergoing resection of pancreatic cancer fare better than their older counterparts.The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection.BRCA germline mutations in Jewish patients with pancreatic adenocarcinomaClinical calculator of conditional survival estimates for resected and unresected survivors of pancreatic cancerPreclinical evaluation of herpes simplex virus armed with granulocyte-macrophage colony-stimulating factor in pancreatic carcinomaA novel recombinant vaccinia virus expressing the human norepinephrine transporter retains oncolytic potential and facilitates deep-tissue imaging.The value of liver magnetic resonance imaging in patients with findings of resectable pancreatic cancer on computed tomography.Pancreatic adenocarcinoma: new strategies for successNovel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy.Prognostic signature for pancreatic cancer: are we close?Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinomaHNRNPA2B1 regulates the epithelial-mesenchymal transition in pancreatic cancer cells through the ERK/snail signalling pathwayEarly onset pancreatic cancer: a controlled trial.Complete Response after Treatment with Neoadjuvant Chemoradiation with Prolonged Chemotherapy for Locally Advanced, Unresectable Adenocarcinoma of the Pancreas.Unique patterns of metastases in common and rare types of malignancy.
P2860
Q28260241-1CA162A9-7CE4-463D-B13E-D4CF4B1AE516Q31102361-B5613AB0-8BC2-4A73-B819-8D89592F26F8Q33599558-D5C270C3-2834-4445-B45C-C8CBC0F65914Q33679644-BDEAF388-277E-47BE-A5EE-3963273737ACQ33684453-AF5BE7EA-4137-4E8D-A7A8-0FEFE51EA180Q33936746-CF2E7534-9C05-4AF0-AFB8-08B790204F0BQ33992146-BAE390C2-CCE3-4931-9583-25F459C38CF2Q34479270-618A6D18-4697-4FBA-A835-15C9B037272BQ34616196-01BAAE15-6FA0-4DF9-920D-8C196D92E655Q34639984-0F833704-51BB-42BD-B0D0-1C2CD749AFD7Q34644418-74D93DE6-AF88-4342-9DCA-F3FC8B5F141AQ34732306-5FCC3D88-F6F5-44F3-A501-B80680243A7AQ34896914-93F1CCA4-F45E-458E-9D3E-21325E37AC26Q35102202-F5FF2677-BF4A-4D35-8903-3637131B377CQ35147520-4042794B-03C1-4085-BE65-05082CB8A533Q35463399-039BE3AC-8C13-42ED-927E-A324AD157CD6Q35738659-4712838E-0071-4001-A456-BA47E39C3922Q35742237-CD794C54-75A3-4E1F-8FCF-09AC6A830A32Q35983594-09CFDA02-F987-47B2-93B4-BE3C80D8E523Q36020137-F924B822-9479-473A-8C0C-9524F368F479Q36023889-E0DC9B51-1377-4826-AB40-098CAF49AB1CQ36097180-5F5D5E3E-2218-4B69-BFF1-79F503E7E81DQ36314356-D28BC32B-D767-40A6-9F11-DA12907FBAF3Q36401628-A1DA207E-C9CF-48B5-87FA-11D701140ADBQ36498482-09EDD43B-076E-42F2-AAE1-0D47F3124DDCQ36693966-D78F9DC3-4A96-4A3C-9D4E-264D83062506Q36747432-F8C620BD-6F21-4F6E-9871-73BB2190751AQ36854437-6AD85F39-88C0-4310-A187-DF6E28DA0D72Q37086658-C2EEC7A5-D4BA-400F-B487-368CFDB42353Q37102488-E023A600-3646-4374-B779-AA10A63B3A46Q37126192-7959FCFB-75F8-468F-B8EE-583B5B36973CQ37147795-DAAC80A9-AFC2-4198-9A8D-03BDDE493A78Q37198628-52609526-F941-401F-BA92-352C9A93D8C2Q37389360-A1A09A09-97AA-4D80-A3D6-9DC981841F9BQ37448935-2CD8E462-988E-40D2-9E9D-FCFBCB39D1E2Q37449401-7C980C15-A177-41A0-9082-C22B9C64CD17Q37576246-8D92B91E-CB38-4CD3-B2C2-D3BB7A561EBDQ37647143-BEC7588C-C314-41CA-8DDB-E5DAAD140D81Q37714700-7CB1D4DD-444A-49EA-A188-6EA47A845443Q37863635-373B2F0E-F7BA-4691-9017-EB363D6458CE
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Pancreatic adenocarcinoma: the actual 5-year survivors.
@en
Pancreatic adenocarcinoma: the actual 5-year survivors.
@nl
type
label
Pancreatic adenocarcinoma: the actual 5-year survivors.
@en
Pancreatic adenocarcinoma: the actual 5-year survivors.
@nl
prefLabel
Pancreatic adenocarcinoma: the actual 5-year survivors.
@en
Pancreatic adenocarcinoma: the actual 5-year survivors.
@nl
P2093
P1476
Pancreatic adenocarcinoma: the actual 5-year survivors.
@en
P2093
Cristina R Ferrone
Daniel G Coit
David Klimstra
Laura Tang
Mithat Gonen
Peter J Allen
P2888
P304
P356
10.1007/S11605-007-0384-8
P577
2007-11-20T00:00:00Z